Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Humbert

Showing results (341-350 of 958) with videos related to

Pageof 96
Sort By:
Presse Medicale (Paris, France : 1983)|August 27, 2013
Drugs induced pulmonary arterial hypertensionAndrei Seferian, Marie-Camille Chaumais, Laurent Savale, et al.
The European Respiratory Journal|May 7, 2021
Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the wallsDavid Montani, Laurent Savale, Antoine Beurnier, et al.
Seminars in Respiratory and Critical Care Medicine|June 27, 2023
Management of Acutely Decompensated Pulmonary HypertensionLaurent Savale, Mithum Kularatne, Anne Roche, et al.
Presse Medicale (Paris, France : 1983)|July 29, 2023
Pulmonary arterial hypertensionAthénaïs Boucly, Christian Gerges, Laurent Savale, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 25, 2013
Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertensionDenis Chemla, Vincent Castelain, Susana Hoette, et al.
The European Respiratory Journal|May 2, 2015
Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertensionYuichi Tamura, Mai Kimura, Makoto Takei, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2007
H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12Veronique Godot, Michel Arock, Gilles Garcia, et al.
Presse Medicale (Paris, France : 1983)|May 4, 2011
[Novel immunopathological approaches to pulmonary arterial hypertension]Frédéric Perros, David Montani, Peter Dorfmüller, et al.
Seminars in Respiratory and Critical Care Medicine|September 17, 2013
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?Laurent Godinas, Christophe Guignabert, Andrei Seferian, et al.
The European Respiratory Journal|September 30, 2021
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance databaseCharles Khouri, Alex Hlavaty, Matthieu Roustit, et al.
Pageof 96

Showing results (341-350 of 958) with videos related to

Sort By:
Pageof 96
Presse Medicale (Paris, France : 1983)|August 27, 2013
Drugs induced pulmonary arterial hypertensionAndrei Seferian, Marie-Camille Chaumais, Laurent Savale, et al.
The European Respiratory Journal|May 7, 2021
Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the wallsDavid Montani, Laurent Savale, Antoine Beurnier, et al.
Seminars in Respiratory and Critical Care Medicine|June 27, 2023
Management of Acutely Decompensated Pulmonary HypertensionLaurent Savale, Mithum Kularatne, Anne Roche, et al.
Presse Medicale (Paris, France : 1983)|July 29, 2023
Pulmonary arterial hypertensionAthénaïs Boucly, Christian Gerges, Laurent Savale, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 25, 2013
Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertensionDenis Chemla, Vincent Castelain, Susana Hoette, et al.
The European Respiratory Journal|May 2, 2015
Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertensionYuichi Tamura, Mai Kimura, Makoto Takei, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2007
H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12Veronique Godot, Michel Arock, Gilles Garcia, et al.
Presse Medicale (Paris, France : 1983)|May 4, 2011
[Novel immunopathological approaches to pulmonary arterial hypertension]Frédéric Perros, David Montani, Peter Dorfmüller, et al.
Seminars in Respiratory and Critical Care Medicine|September 17, 2013
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?Laurent Godinas, Christophe Guignabert, Andrei Seferian, et al.
The European Respiratory Journal|September 30, 2021
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance databaseCharles Khouri, Alex Hlavaty, Matthieu Roustit, et al.
Pageof 96